Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q3 2015 · 10-Q
Revenue$36.63M$36.63M+29.6% vs Q3 2014 Net Income-$5.41M-$5.41MN/M vs Q3 2014 EPS Diluted-$34.43-$34.43N/M vs Q3 2014 Gross Profit$707,000−81.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$5,396,000N/M Free Cash Flowderived-$5,437,000N/M Margins · derivedGross margin1.9%−11.7 pt vs Q3 2014
Operating margin-18.2%−6.8 pt vs Q3 2014
Net margin-14.8%+1.0 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 12, 2015 · 43 d after period end